Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study

<p>Abstract</p> <p>Background</p> <p>While the factors for poor adherence for treatment with statins have been highlighted, the impact of their combination on adherence is not clear.</p> <p>Aims</p> <p>To estimate adherence for statins and whether it differs according to the number of cardiovascular risk factors.</p> <p>Methods</p> <p>A cohort study was conducted using data from the main French national health insurance system reimbursement database. Newly treated patients with statins between September 1 and December 31, 2004 were included. Patients were followed up 15 months. The cohort was split into three groups according to their number of additional cardiovascular risk factors that included age and gender, diabetes mellitus and cardiovascular disease (using co-medications as a <it>proxy</it>). Adherence was assessed for each group by using four parameters: <it>(i) </it>proportion of days covered by statins, <it>(ii) </it>regularity of the treatment over time, <it>(iii) </it>persistence, and <it>(iv) </it>the refill delay.</p> <p>Results</p> <p>16,397 newly treated patients were identified. Of these statin users, 21.7% did not have additional cardiovascular risk factors. Thirty-one percent had two cardiovascular risk factors and 47% had at least three risk factors. All the parameters showed a sub-optimal adherence whatever the group: days covered ranged from 56% to 72%, regularity ranged from 23% to 33% and persistence ranged from 44% to 59%, but adherence was better for those with a higher number of cardiovascular risk factors.</p> <p>Conclusions</p> <p>The results confirm that long-term drug treatments are a difficult challenge, particularly in patients at lower risk and invite to the development of therapeutic education.</p

Use of reimbursement claims databases for the measurement of medication adherence

L’efficacité d’une thérapeutique repose, en grande partie, sur la bonne observance de la prescription. Une mauvaise observance est susceptible de provoquer un échec thérapeutique et une escalade dans les traitements. Elle est également génératrice de surcoûts pour le système de protection sociale. La base de données Erasme, base de remboursement du régime général de l’assurance maladie (Cnam-TS), constitue une source d’information importante pour la mesure de l’utilisation des médicaments et donc, possiblement, de l’observance. Hors, depuis de nombreuses années, il a été proposé des descripteurs de l’observance calculable à partir des remboursements de différents systèmes d’assurance maladie dans le monde. Le but de ce travail était de : - recenser ces indicateurs et les appliquer à la base Erasme ; - proposer de nouveaux indicateurs ; - catégoriser ces indicateurs. Dans une première partie nous faisons l’état des lieux de la notion et du concept d’observance médicamenteuse et de sa mesure à partir des bases de données de remboursement. Dans une deuxième partie, nous présentons la base Erasme et proposons des nouveaux indicateurs. Afin d’illustrer nos propos, nous présentons les études que nous avons réalisé à partir de l’étude de médicaments ayant des profils de consommation différents : traitement au long cours d’une affection symptomatique (asthme), traitement au long cours d’une affection asymptomatique (hypercholestérolémie), traitement au long cours d’une affection grave (diabète), traitement « minute » (infection urinaire) et un traitement de durée moyenne (contraception orale).The efficacy of a therapeutic response depends largely on good adherence to the prescription. Poor adherence may lead to therapeutic failure and an escalation of treatment. Furthermore, this generates excess cost for the health insurance system. The Erasme reimbursement database of the largest health insurance system in France (régime général de l'assurance maladie, Cnam-TS), represents an important source of information on the use of medicines, and, therefore, possibly adherence. This is particularly the case as several indicators have been proposed to describe adherence from reimbursements in the different health insurance systems around the world. The objective of the current work was to: - identify the indicators and to apply these to the Erasme database; - propose new indicators; - categorise these indicators. The first part introduces the notion and concept of medication adherence and its measurement from reimbursement databases. The second part describes the Erasme database and the propositions for new indicators. This will then be illustrated by the studies that we have performed on medicines that have different profiles of use: long-term treatment of symptomatic disease (asthma), long-term treatment of asymptomatic disease (hypercholesterolaemia), long-term treatment of serious disease (diabetes), short-term treatment (urinary infection), and medium-term treatment (oral contraceptives)

How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database

International audienc

Utilisation des bases de données de remboursement dans la mesure de l'observance des médicaments

L efficacité d une thérapeutique repose, en grande partie, sur la bonne observance de la prescription. Une mauvaise observance est susceptible de provoquer un échec thérapeutique et une escalade dans les traitements. Elle est également génératrice de surcoûts pour le système de protection sociale. La base de données Erasme, base de remboursement du régime général de l assurance maladie (Cnam-TS), constitue une source d information importante pour la mesure de l utilisation des médicaments et donc, possiblement, de l observance. Hors, depuis de nombreuses années, il a été proposé des descripteurs de l observance calculable à partir des remboursements de différents systèmes d assurance maladie dans le monde. Le but de ce travail était de : - recenser ces indicateurs et les appliquer à la base Erasme ; - proposer de nouveaux indicateurs ; - catégoriser ces indicateurs. Dans une première partie nous faisons l état des lieux de la notion et du concept d observance médicamenteuse et de sa mesure à partir des bases de données de remboursement. Dans une deuxième partie, nous présentons la base Erasme et proposons des nouveaux indicateurs. Afin d illustrer nos propos, nous présentons les études que nous avons réalisé à partir de l étude de médicaments ayant des profils de consommation différents : traitement au long cours d une affection symptomatique (asthme), traitement au long cours d une affection asymptomatique (hypercholestérolémie), traitement au long cours d une affection grave (diabète), traitement minute (infection urinaire) et un traitement de durée moyenne (contraception orale).The efficacy of a therapeutic response depends largely on good adherence to the prescription. Poor adherence may lead to therapeutic failure and an escalation of treatment. Furthermore, this generates excess cost for the health insurance system. The Erasme reimbursement database of the largest health insurance system in France (régime général de l'assurance maladie, Cnam-TS), represents an important source of information on the use of medicines, and, therefore, possibly adherence. This is particularly the case as several indicators have been proposed to describe adherence from reimbursements in the different health insurance systems around the world. The objective of the current work was to: - identify the indicators and to apply these to the Erasme database; - propose new indicators; - categorise these indicators. The first part introduces the notion and concept of medication adherence and its measurement from reimbursement databases. The second part describes the Erasme database and the propositions for new indicators. This will then be illustrated by the studies that we have performed on medicines that have different profiles of use: long-term treatment of symptomatic disease (asthma), long-term treatment of asymptomatic disease (hypercholesterolaemia), long-term treatment of serious disease (diabetes), short-term treatment (urinary infection), and medium-term treatment (oral contraceptives).BORDEAUX2-Bib. électronique (335229905) / SudocSudocFranceF

Temperature and Dilatation Estimation for Modern Semiconductor Devices

This paper presents a new approach for measuring physical variables on micro- electronic components. An optical system is used to simultaneously quantify the surface temperature of a component and its expansion. This double acquisition is realized by a Michelson interferometer coupled with a Charge Coupled Device (CCD) line device. To validate this method, the temperature measurements were directly compared with the results obtained by an infrared camera and by a measurement of variation of I (V). The displacement measurements were compared with those obtained by a laser 3D vibrometer, whose physical principle is completely different. Consistent results were obtained regarding the different techniques

Temperature and Dilatation Estimation for Modern Semiconductor Devices

International audienc

Temperature and Dilatation Estimation for Modern Semiconductor Devices

International audienceThis paper presents a new approach for measuring physical variables on micro- electronic components. An optical system is used to simultaneously quantify the surface temperature of a component and its expansion. This double acquisition is realized by a Michelson interferometer coupled with a Charge Coupled Device (CCD) line device. To validate this method, the temperature measurements were directly compared with the results obtained by an infrared camera and by a measurement of variation of I (V). The displacement measurements were compared with those obtained by a laser 3D vibrometer, whose physical principle is completely different. Consistent results were obtained regarding the different techniques

Temperature and Dilatation Estimation for Modern Semiconductor Devices

International audienceThis paper presents a new approach for measuring physical variables on micro- electronic components. An optical system is used to simultaneously quantify the surface temperature of a component and its expansion. This double acquisition is realized by a Michelson interferometer coupled with a Charge Coupled Device (CCD) line device. To validate this method, the temperature measurements were directly compared with the results obtained by an infrared camera and by a measurement of variation of I (V). The displacement measurements were compared with those obtained by a laser 3D vibrometer, whose physical principle is completely different. Consistent results were obtained regarding the different techniques

Arch Cardiovasc Dis

Myocardial infarction is a major cause of morbidity and mortality. Guidelines have been published to optimize medical care and involve optimization of the care pathway and hospital-city coordination. To describe the myocardial infarction care pathway during the year following hospital discharge, and the use of and adherence to secondary prevention drugs. A cohort study was conducted using data from the main French health insurance reimbursement database of the ex-Aquitaine region. Information about the medical and pharmaceutical care of hospitalized patients in 2018 was collected for 12 months. Medication adherence was assessed by using the proportion of days covered by the treatment and persistence. A total of 3015 patients were included, and the mean age was 66 years. Almost 76% of the patients had a reimbursement for BAS (combined prescription of beta-blocker/antiplatelet/lipid-lowering drug), BASI (combined prescription of beta-blocker/antiplatelet/lipid-lowering drug/angiotensin-converting enzyme inhibitor) or AS (combined prescription of antiplatelet/lipid-lowering drug) treatment. Medication adherence was around 83% for aspirin and 75% for lipid-lowering drugs for the 1-year persistence. During the same time, the proportion of days covered was suboptimal. Almost 4% of patients died after leaving hospital, 45% went to a cardiac rehabilitation centre and 23% had at least one hospital readmission, whatever the reason. Patients had a mean number of 11 general practitioner consultations during the year. Almost 41% of patients did not have a consultation with a cardiologist, and 38.4% had at least two consultations. Rehabilitation and general practitioner consultations were associated with adherence. These new results provide clear information on the medical care environment of patients, and help us to improve care transition. Close collaboration between healthcare practitioners is very important in the early stages of outpatient follow-up